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Informed consent was obtained from the patient’s parents for 
publication of this case report.
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To the Editor: Chikungunya fever is a febrile ill-
ness caused by mosquito-transmitted chikungunya virus 
(CHIKV; genus Alphavirus, family Togaviridae). Clinical 
signs and symptoms typically begin with high-grade fever 
after an incubation period of 2–4 days (1). Other common 
symptoms include polyarthralgia, which is usually sym-
metric and involves multiple and distal joints, and skin in-
volvement manifesting as a macular or maculopapular rash 
(2). Peripheral lymphadenopathy (most often cervical) and 
conjunctivitis might also occur (3).
Since late 2013, several outbreaks of illness caused by 
CHIKV have occurred in the Americas, including South 
America, the Caribbean, and the United States, which are 
outside this virus’s former distribution area (3). Although 
autochthonous transmission of chikungunya fever has 
been reported in most Caribbean islands, only imported 
cases have been previously reported in Cuba (4). As in-
creased numbers of US tourists visit Cuba after improved 
diplomatic relations in July 2015, reports of chikungunya 
fever cases in Cuba are of interest for travelers and health-
care providers. We describe a case of autochthonous chi-
kungunya fever in a man who had traveled from Japan 
to Cuba.
In late February 2016, a previously healthy 27-year-
old man visited a travel clinic in the National Center for 
Global Health and Medicine (Tokyo, Japan) with fever and 
rash. In mid-February, he had traveled to Havana and San-
tiago de Cuba in Cuba by way of Toronto, Ontario, Canada, 
for 11 days of sightseeing. He used no insect repellent dur-
ing the trip and was unaware of any mosquito bites. When 
he sought care, he reported a high-grade fever (39°C) for 
24 hours and several symptoms since the day of his return: 
retro-orbital pain, malaise, congested conjunctivas, and a 
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rash on his anterior chest. Over the previous few days, his 
knee and ankle joints also had mild arthralgia.
On physical examination, the patient’s body tempera-
ture was 38.7°C, and he had congested bulbar conjuncti-
vas, cervical lymphadenopathy, and maculopapular rashes 
on his face, trunk, and extremities (online Technical Ap-
pendix Figure, panels A, B, http://wwwnc.cdc.gov/EID/
article/22/9/16-0603-Techapp1.pdf). Laboratory tests re-
vealed lymphopenia (701 cells/μL) and mild elevation of 
C-reactive protein (0.87 mg/dL). Real-time reverse tran-
scription PCR detected CHIKV RNA in his serum sample. 
Phylogenetic analysis was performed on the basis of nucle-
otide sequences of the E1 gene from the sample by using 
the maximum likelihood method with 1,000 bootstrap rep-
licates and MEGA 6.0 software (5). This sequence (Gen-
Bank accession no. LC146714) was 99.9% (1,319 of 1,320 
sequences) was identical to that of a CHIKV strain isolated 
from the Dominican Republic in 2014 (GenBank accession 
no. KR559498) (Figure; online Technical Appendix Table). 
The positive-to-negative ratio of CHIKV-specific IgM was 
negative in a serum sample collected on day 4 after fever 
onset but was positive in a sample taken 7 days later (pos-
itive-to-negative ratios 5.6 and 21.9, respectively; ratios 
were considered positive if >11). Because the patient’s se-
rum samples contained no dengue or Zika virus, infections 
from these viruses were excluded, and chikungunya fever 
was diagnosed.
One day after the patient’s first visit to the clinic, 
rashes on his extremities became worse and slightly itchy. 
Pain also developed in his wrists and metacarpophalangeal 
joints of his hand, followed by cervical pain and slight ri-
gidity on the hand’s distal and proximal interphalangeal 
joints. The patient was initially treated with acetaminophen 
(600 mg 3×/d 2 d); after diagnosis of chikungunya fever, 
he was treated with loxoprofen and rebamipide (60 mg and 
100 mg, respectively, 3×/d 7 d). The congested bulbar con-
junctivas and rash on his trunk improved; soon thereafter, 
all symptoms resolved.
CHIKV was first isolated in 1953 in Tanzania during 
an epidemic outbreak in East Africa (6). Mosquitoes, pre-
dominantly Aedes aegypti and Ae. albopictus, transmit the 
virus (2). Aedes spp. are also the common vector of dengue 
and Zika viruses, and localized dengue outbreaks occurred 
in Santiago de Cuba in 1997 and in Havana in 2000–2001 
because of the persistence of Aedes mosquito infestation in 
Cuba (7,8). Furthermore, autochthonous Zika virus infec-
tion in Cuba was first reported in March 2016 (9).
Differentiation between chikungunya fever, dengue 
fever, and Zika virus infection is difficult because of 
similar signs and symptoms and common endemic areas. 
We suspected chikungunya fever in this patient because 
of high-grade fever and maculopapular rash, although he 
also had prominent conjunctivitis, which is uncommon in 
CHIKV-infected patients but frequent in persons infected 
with Zika virus (3,10). Phylogenetic analysis of the virus 
isolated from this patient revealed a high sequence ho-
mology with recent strains discovered in Caribbean and 
Central American countries in 2014. Homology between 
the isolate from this patient and a 2014 Asian lineage 
isolate from the Dominican Republic was 99.92% at the 
nucleotide level. 
This case highlights the potential threat of a chikun-
gunya fever outbreak in Cuba. Physicians should consider 
chikungunya fever in the differential diagnosis for febrile 
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Figure. Phylogenetic analysis of 
the chikungunya virus sequence 
obtained from a patient returning 
to Japan (in bold) from Cuba in 
February 2016, compared with 
reference sequences. Virus 
lineages are shown at right. Scale 
bar represents substitutions per 
nucleotide position. ECSA, Eastern/
Central/South African lineage.
travelers returning from Cuba with a rash, similarly to pa-
tients returning from other countries in which dengue fever, 
chikungunya fever, and Zika virus infection are endemic. 
Preventive measures, including advice to travelers on 
proper use of insect repellents, are critical for preventing 
CHIKV infection.
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To the Editor: Zika virus is an emerging virus that has 
spread to most countries in Latin America and the Caribbe-
an (1,2). It is transmitted by mosquitoes and through sexual 
intercourse (3). Most persons infected with Zika virus are 
asymptomatic or experience mild symptoms (4). However, 
in a pregnant woman, infection may cause severe pregnan-
cy and birth complications, most notably microcephaly in 
children infected in utero (5–7). Zika virus infection might 
also be associated with an increased incidence of Guillain-
Barré syndrome (8). Thus, the virus represents a threat to 
healthcare workers who manage infected patients or diag-
nostic samples and researchers who work with infectious 
virus in laboratories. 
Working with Zika virus, a Biosafety Level 2 (BSL-
2) pathogen in the European Union, except for the United 
Kingdom (where it is BSL-3), requires specific safety pre-
cautions (9). No inactivation data specific for Zika virus 
are available (9); consequently, disinfection guidelines are 
based on protocols to inactivate other flaviviruses. To gain 
experimental evidence regarding inactivation and disinfec-
tion for Zika virus, we determined its susceptibility to vari-
ous disinfectants and inactivation methods.
To test susceptibilities, we determined the 50% tissue 
cell infectious dose per milliliter (TCID50/mL) (10) of the 
Zika virus MR766 strain (1) before and after the virus was 
exposed to disinfectants or other inactivation procedures 
(online Technical Appendix,  http://wwwnc.cdc.gov/EID/
article/22/9/16-0664-Techapp1.pdf). We then determined 
the effect of alcohol-based disinfectants on viral infectiv-
ity. Using Zika virus stock containing 2.5% fetal calf serum 
(FCS) mixed 3:10 (vol/vol) with indicated alcohols, we 
incubated the mixture for 1 minute and then used it for in-
fection (Figure, panel A). All alcohols entirely inactivated 
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